Plain-English translation of NCT05430971 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is building a worldwide registry—a centralized database—of patients diagnosed with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare blood cancer. By collecting information about patients' diagnoses, treatments, and outcomes from hospitals around the globe, researchers hope to learn more about this disease and identify the best ways to treat it.
BPDCN is a very rare cancer, and doctors don't yet agree on the best treatment approach. By gathering data from many patients across different countries, researchers can spot patterns, understand which treatments work best, and develop new therapies to help patients with this disease.
You likely qualify if…
You likely don't qualify if…
If you join, your participating hospital or clinic will collect information about your diagnosis, medical history, any treatments you receive, and how you respond to those treatments. Your doctors will also share your medical records and outcomes with the registry. This is an ongoing database, so your information may be tracked over time as part of the study.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States
Armenia
Canada